Palisade Bio Inc (PALI) Actualités

Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies

– Company remains committed to its mission to become a leader in developing differentiated product candidates...

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis...

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade...

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence...

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local...

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy...

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Live video webcast on Wednesday, June 26th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE...

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise...